28338376|t|Pembrolizumab for the treatment of non-small cell lung cancer
28338376|a|In the last years, a spectacular development of immunotherapeutic agents aimed at the PD-1 / PD-L1 axis has taken place. This development of these checkpoint inhibitors has greatly influenced our approach to the treatment of lung cancer in first and second line. The limited toxicity profile and the ability to treat for prolonged periods, even in smokers, is a welcome expansion of the therapeutic arsenal of the oncologist. Areas covered: This review highlights the results of recent clinical trials on pembrolizumab for the treatment of non-small cell lung cancer. The authors discuss both first and second line treatment with pembrolizumab as monotherapy and in combination therapies. Additionally, implications of the PD-L1 immunohistochemistry assay with the 22C3 antibody and its use in clinical practice and trials is discussed. Expert commentary: A higher overall response, overall survival and a moderate toxicity profile is observed with the use of pembrolizumab, compared to chemotherapy, in both first and second line. These promising results have already translated into the registration of pembrolizumab in first and second line in patients with a high expression of PD-L1. However, as PD-L1 staining does not sufficiently discriminate responders from non-responders for all checkpoint inhibitors, there still is a need for a better predictive biomarker.
28338376	0	13	Pembrolizumab	T116,T121,T129	C3658706
28338376	22	31	treatment	T061	C0087111
28338376	35	61	non-small cell lung cancer	T191	C0007131
28338376	95	106	development	T169	C1527148
28338376	110	134	immunotherapeutic agents	T121,T129	C0876248
28338376	148	152	PD-1	T116,T129,T192	C2986635
28338376	155	160	PD-L1	T129	C4300350
28338376	188	199	development	T169	C1527148
28338376	209	230	checkpoint inhibitors	T120	C0243077
28338376	274	283	treatment	T061	C0087111
28338376	287	298	lung cancer	T191	C0242379
28338376	302	307	first	T061	C1708063
28338376	312	323	second line	T061	C1710038
28338376	329	336	limited	T169	C0439801
28338376	337	345	toxicity	T037	C0013221
28338376	373	378	treat	T061	C0087111
28338376	383	392	prolonged	T079	C0439590
28338376	393	400	periods	T079	C1948053
28338376	410	417	smokers	T033	C0337664
28338376	476	486	oncologist	T097	C0259990
28338376	508	514	review	T170	C0282443
28338376	530	537	results	T169	C1274040
28338376	548	563	clinical trials	T062	C0008976
28338376	567	580	pembrolizumab	T116,T121,T129	C3658706
28338376	589	598	treatment	T061	C0087111
28338376	602	628	non-small cell lung cancer	T191	C0007131
28338376	634	641	authors	T097	C3812881
28338376	655	660	first	T061	C1708063
28338376	665	686	second line treatment	T061	C1710038
28338376	692	705	pembrolizumab	T116,T121,T129	C3658706
28338376	709	720	monotherapy	T061	C0087111
28338376	728	749	combination therapies	T061	C0013218
28338376	785	790	PD-L1	T129	C4300350
28338376	791	817	immunohistochemistry assay	T059	C0020980
28338376	827	840	22C3 antibody	T116,T129	C0003241
28338376	849	852	use	T169	C0457083
28338376	856	873	clinical practice	T062	C0008967
28338376	878	884	trials	T062	C0008976
28338376	920	926	higher	T080	C0205250
28338376	927	943	overall response	T033	C3272903
28338376	945	961	overall survival	T081	C4086681
28338376	968	976	moderate	T080	C0205081
28338376	977	985	toxicity	T037	C0013221
28338376	1015	1018	use	T169	C0457083
28338376	1022	1035	pembrolizumab	T116,T121,T129	C3658706
28338376	1049	1061	chemotherapy	T061	C3665472
28338376	1071	1076	first	T061	C1708063
28338376	1081	1092	second line	T061	C1710038
28338376	1110	1117	results	T169	C1274040
28338376	1151	1163	registration	T058	C1514821
28338376	1167	1180	pembrolizumab	T116,T121,T129	C3658706
28338376	1184	1189	first	T061	C1708063
28338376	1194	1205	second line	T061	C1710038
28338376	1209	1217	patients	T101	C0030705
28338376	1225	1229	high	T080	C0205250
28338376	1230	1240	expression	T045	C1171362
28338376	1244	1249	PD-L1	T129	C4300350
28338376	1263	1268	PD-L1	T129	C4300350
28338376	1269	1277	staining	T059	C0487602
28338376	1313	1323	responders	T033	C0919876
28338376	1329	1343	non-responders	T033	C0919875
28338376	1352	1373	checkpoint inhibitors	T120	C0243077
28338376	1410	1420	predictive	T080	C0681890
28338376	1421	1430	biomarker	T201	C0005516